Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2016

View Archived Issues

Data presented on brentuximab vedotin in germ-cell tumors

Daiichi Sankyo divulges new S1PL inhibitors

Aryl-sulfonamides as isoform-selective inhibitors of Nav1.7

A first-in-human study of RG-7666

Allied-Bristol Life Sciences launches new subsidiary iBeCa Therapeutics

Microlin Bio to acquire Marina's nucleic acid therapeutic assets

Mologen announces extension of TEACH study

Vraylar now available in the U.S. as treatment of adults with bipolar mania and schizophrenia

FDA grants breakthrough therapy designation for NI-0501 for the treatment of primary HLH

MP-376 receives QIDP designation

Sanofi and DiCE Molecules announce research collaboration

BioBlast Pharma announces positive final results from HOPEMD phase II study

Istituto Europeo di Oncologia patents KDM1A inhibitors

Synergistic anticancer effects of GEN-1 combined with Avastin and Doxil in preclinical studies

Merck & Co. discloses DGAT-2 inhibitors

AstraZeneca exercises option to acquire rights to Orexo's OX-CLI program

Nippon Shinyaku develops JAK1 inhibitors

TES Pharma presents ACMSD inhibitors

Amgen divulges Mcl-1 inhibitors

Grant supports City of Hope's development of treatment for Canavan disease

Cleveland BioLabs updates progress of entolimod pre-EUA review

MDxHealth launches SelectMDx for Prostate Cancer test in U.S.

Proof of concept achieved in phase IIa trial of VTP-43742 for psoriasis

VESTRI safety study of Advair Diskus in children meets primary endpoint

FDA approves Kovaltry for hemophilia A in children and adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...